Wake Research Associates
Welcome,         Profile    Billing    Logout  
 10 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Investigator, Principle
NCT05198310 / 2022-000169-42: Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor

Completed
2
145
Europe, US, RoW
KPL-404, abiprubart, Placebo
Kiniksa Pharmaceuticals, Ltd., Kiniksa Pharmaceuticals, Ltd.
Arthritis, Rheumatoid
02/24
05/24
THB335-101, NCT06425861: A First in Human Trial Evaluating THB335 in Healthy Participants

Recruiting
1
56
US
THB335 single dose, Single dose placebo, THB335 fasted/fed, Placebo fasted/fed, THB335 multiple dose, Multiple dose placebo
Third Harmonic Bio, Inc.
Healthy
03/25
03/25
NCT06372782: Comparing Pain, Safety and Effectiveness of Restylane Skinboosters Vital Lido and Vital Without Lido in Dorsal Hand

Active, not recruiting
N/A
90
RoW
Restylane Skinboosters Vital Lidocaine, Restylane Vital
Galderma R&D
Skin Aging of Dorsal Hands
06/24
08/24
McKenzie, Mark
QWINT-1, NCT05662332: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
795
US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, T2D
07/24
07/24
SURMOUNT-5, NCT05822830: A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

Completed
3
751
US
Tirzepatide, LY3298176, Semaglutide
Eli Lilly and Company
Obesity, Overweight
11/24
11/24
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT05468736: Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

Active, not recruiting
2/3
3600
Europe, US, RoW
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), NVX-CoV2373, Placebo, Sodium chloride 0.9% (BP, sterile)
Novavax
COVID-19
01/24
10/25
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

Completed
2
797
NA
ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline
AEON Biopharma, Inc., PPD
Migraine
06/24
08/24
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects

Recruiting
2
240
US, RoW
HM15211, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
05/26
11/26
NCT03952364: The PRECIOUS Study: Predicting Crohn's & ColitIs Outcomes in the United States

Recruiting
N/A
200
US
PredictSURE IBD™
PredictImmune Ltd, The Crohn's and Colitis Foundation
Crohn Disease, Ulcerative Colitis, IBD, Inflammatory Bowel Diseases
06/22
06/22
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Active, not recruiting
N/A
44467
US
Guardant Health, Inc., Premier Research Group plc
Colorectal Cancer
03/24
12/25
Turner, Brandy
No trials found
Majeed, Irfan
No trials found

Download Options